Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition that can be caused by genetic mutations or aging, and is characterized by accumulating heart damage that ultimately leads to symptoms of heart failure. In ATTR-CM,…
The most common signs of transthyretin amyloid cardiomyopathy (ATTR-CM) are those typically associated with heart failure, although problems in the nervous system or other tissues can also occur. ATTR-CM is a type of cardiac amyloidosis,…
A diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is typically reached through a series of tests to identify signs of the disease and rule out related disorders. ATTR-CM is a type of heart amyloidosis, a group…
The treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) is a multidisciplinary effort involving interventions to slow disease progression and manage symptoms. ATTR-CM is a form of amyloidosis, where protein clumps, called amyloid deposits, accumulate in tissues.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart disease that’s typically caused by genetic mutations or aging. Determining the root cause of ATTR-CM can help guide treatment decisions, understand prognosis, and determine if family…
Latest News & Community Perspectives
Discussion
People carrying the p.V142I mutation in the TTR gene — which is mostly associated with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) — often have polyneuropathy, or damage to multiple nerves, a U.S. study shows. But…
Discussion
Higher blood levels of fibroblast growth factor 23 (FGF23) — a bone-derived hormone — are associated with higher levels of established markers of heart damage and more advanced disease in people with transthyretin amyloid…
Discussion
An artificial intelligence (AI) model that analyzes the results of echocardiograms may help predict the likelihood of transthyretin amyloid cardiomyopathy (ATTR-CM) in people at high risk for the condition, a study suggested. The…
Discussion
Researchers have identified a common structure among toxic transthyretin (TTR) clumps, called amyloid fibrils, in heart tissue from people carrying mutations linked to hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). Such structural similarity contrasts with…
Discussion
In people with transthyretin amyloid cardiomyopathy (ATTR-CM), the buildup of faulty transthyretin (TTR) protein in the heart may contribute to blood clots that block capillaries, the smallest blood vessels, and trigger molecular events that…
Discussion
People with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in more recent clinical trials show less advanced disease and improved survival compared with those in earlier studies, likely reflecting early diagnosis and advances in treatment. That’s according…
Discussion
New analyses back the use of the approved therapy Amvuttra (vutrisiran) as an initial treatment for people with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) who have risk factors such as abnormal heart rhythms or…
Discussion
New analyses suggest Attruby (acoramidis) may reduce the risk of outpatient worsening heart failure, with differences seen within 30 days and sustained through 30 months in adults with transthyretin amyloid cardiomyopathy (ATTR-CM). The analyses…
Discussion
The oral therapy acoramidis has been approved in Brazil, to be sold as Beyonttra, for treating adults with hereditary or wild-type transthyretin amyloid cardiomyopathy (ATTR-CM). The regulatory clearance from the Agência Nacional de Vigilância…
Discussion
The U.S. Food and Drug Administration (FDA) has granted fast track designation to coramitug, an experimental treatment in late-stage clinical testing for transthyretin amyloid cardiomyopathy (ATTR-CM). The FDA gives this designation to investigational…